These novel treatments, Semaglutide , represent a significant advancement in treating obesity and possibly associated ailments . They are grouped as GLP-1 pathway stimulators, meaning these substances to emulate the endogenous GLP-1 peptide, stimulating glucose release and reducing food intake. D